$SBEV

SPLASH BEVERAGE GROUP, INC. (SBEV): Unregistered Sales of Equity Securities

SPLASH BEVERAGE GROUP, INC. (SBEV) filed an SEC Form 8-K — Unregistered Sales of Equity Securities. false 0001553788 0001553788 2026-07-06 2026-07-06 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Repor

Original reporting
Published Jul 10, 2026, 8:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 10, 2026, 8:32 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefCorporate actions
Primary signal
$SBEV
Bearish
medium confidence
Mentioned
$SBEV
Relevance
5/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$SBEVBearishMed
01

Why it matters

The disclosure quantifies the share issuance and gross proceeds, making the dilution magnitude and timing explicit for the recent window (June 30 to July 8).

02

Market read

This is a concrete, time-bounded dilution datapoint that can affect near-term valuation and trading behavior for SBEV.

03

What to watch

Traders should check whether the ELOC is likely to continue at similar pace, and whether the registration statement effectiveness (June 22, 2026) enables faster resales that could amplify selling pressure.

Relevance 5/10Novelty 6/10Timing: Filed July 10, 2026 for sales occurring June 30 to July 8, 2026.

Background

SBEV filed an 8-K Item 3.02 describing unregistered equity sales under a previously disclosed Securities Purchase Agreement (ELOC) with C/M Capital Master Fund, LP.

Company-level read

Ticker impact

$SBEVBearishMedium confidence
Context

SBEV disclosed an ELOC-driven issuance of 9,232,047 shares from June 30 to July 8, 2026 for $1.265M gross proceeds.

Expected impact

Near-term downside bias or elevated volatility as traders price continued share issuance under the ELOC.

Evidence & confidence

An 8-K Item 3.02 reports unregistered sales under an equity purchase agreement, directly implying incremental shares hitting the market and potential overhang.

Market effects

Adds to the broader microcap narrative that equity lines can create persistent dilution overhang.

No clear regional spillover beyond US microcap sentiment.

Limited global relevance; primarily affects SBEV’s US trading and liquidity expectations.

Counterpoint

If proceeds are used to fund operations or growth, the dilution may be offset by improved runway, reducing long-term impairment risk.

Key entities

  • SPLASH BEVERAGE GROUP, INC.

    Company reporting unregistered sales of equity securities under an ELOC agreement.

  • C/M Capital Master Fund, LP

    Counterparty under the Securities Purchase Agreement (ELOC) referenced in the filing.

Related articles

$SBEVMed

Splash Beverage Group (SBEV) Stock Is Trending Overnight— Here's Why It Jumped 64% After Hours Splash Bev

Splash Beverage Group Inc. (NYSE:SBEV) shares are trending on Friday. Shares of the Florida-based company climbed 64.10% to $0.57 after the bell on Thursday. The surge in the late trading session follows an intraday gain of 7.07% which closed the SBEV at $0.35, according to Benzinga Pro data. Splash Beverage Group, which engages in the manufacturing, distribution, marketing, and sale of various beverages, experienced an exceptionally elevated trading session on Thursday.

$SBEVMed

Splash Beverage Group Expands CannEpil Platform into Veterinary Therapeutics, Establishing Second FDA-Regulated Pharmaceutical Development Program

Splash Beverage Group (NYSE American: SBEV) said it expanded its exclusive global CannEpil license to cover veterinary therapeutics. The company plans initial evaluation for companion-animal oncology and chronic pain, pursuing FDA Center for Veterinary Medicine INAD and Conditional Approval pathways. Splash will pay Argent BioPharma a 10% royalty on veterinary net revenues.

$SBEVMedAI 8/10

Splash Beverage Group Announces Significant Balance Sheet Improvement and Board Approval of Reverse Stock Split as Company Continues Strategic Transformation

Splash Beverage Group (NYSE American: SBEV) said it settled legacy creditor claims totaling about $3.3 million for about $550,000 cash, expecting an approximate $2.75 million gain from debt extinguishment, subject to final accounting. Its board approved a 1-for-4 reverse stock split to support NYSE American minimum price compliance, reducing shares from ~25.2M to ~6.3M, effective July 27, 2026.

$SBEVMed

Splash Beverage Group Receives NYSE American Acceptance of Compliance Plan, Establishing Defined Path Toward Continued Listing and Strategic Transformation

Splash Beverage Group (NYSE American: SBEV) said NYSE American accepted its plan to regain continued listing compliance and granted a compliance period through Jan. 29, 2027, after the company submitted the plan on May 29, 2026. The company said it will execute strategic initiatives while maintaining its listing.

$SBEVMedAI 8/10

SPLASH BEVERAGE GROUP ACQUIRES EXCLUSIVE GLOBAL RIGHTS TO CANNEPIL®, AN EPILEPSY THERAPY WITH ESTABLISHED EUROPEAN PATIENT ACCESS, FDA ENGAGEMENT AND U.S. DEVELOPMENT POTENTIAL

Splash Beverage Group (NYSE American: SBEV) said it signed an exclusive global licensing deal with Argent BioPharma (ASX/LSE: RGT) for CannEpil, a cannabinoid-based investigational therapy for drug-resistant epilepsy. CannEpil is approved for distribution in multiple countries and has initiated U.S. pre-IND/IND steps. Splash received a $1M investment commitment and will issue $5.5M preferred equity; Argent debt (~$5M) is forgiven. Argent earns a 15% net-revenue royalty.

$SBEVMed

Splash Beverage Group Secures Exclusive Global Rights To CannEpil For Drug- Resistant Epilepsy

Splash Beverage Group (SBEV) said it secured exclusive global licensing rights to CannEpil, a pharmaceutical-grade cannabinoid therapy for drug-resistant epilepsy, from Argent BioPharma (RGT.AX). CannEpil has patient access in Ireland, UK, Germany and Australia under EU-GMP, with Ireland MCAP reimbursement support and UK Named Patient Request import/prescription. SBEV cited pre-IND/IND progress for U.S. development.